Aura BiosciencesAURA +14.92%35 Current Ratio is 7.09 as of Mar. 2026, which is 50% below its 10-year median of 14.22. GuruFocus rates AURA with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Aura Biosciences ranks better than 68.82% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aura Biosciences's current ratio for the quarter that ended in Mar. 2026 was 7.09.
Aura Biosciences has a current ratio of 7.09. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Aura Biosciences's Current Ratio or its related term are showing as below:
AURA'
s Current Ratio Range Over the Past 10 Years
Min: 5.42 Med: 14.22 Max: 27.9
Current: 7.09
During the past 7 years, Aura Biosciences's highest Current Ratio was 27.90. The lowest was 5.42. And the median was 14.22.
AURA's Current Ratio is ranked better than 68.82% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs AURA: 7.09
Aura Biosciences (NAS:AURA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Aura Biosciences Current Ratio Related Terms
Aura Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Aura Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aura Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aura Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aura Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Aura Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aura Biosciences (AURA) has a Current Ratio of 7.09 as of Mar. 2026. This is 50% below median its historical median of 14.22. Over the past decade, Aura Biosciences' Current Ratio has ranged from 5.42 to 27.90. According to the industry distribution chart, Aura Biosciences ranks #440 out of 1411 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Aura Biosciences' Current Ratio too high?
Aura Biosciences' current Current Ratio of 7.09 is 50% below median its 10-year median of 14.22. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 27.90. The Biotechnology industry median Current Ratio is 3.91. Aura Biosciences' value of 7.09 is 81.3% above this industry median. Based on the distribution chart, Aura Biosciences ranks #440 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aura Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' Current Ratio compare to NVCT and CADL?
According to the Biotechnology industry distribution chart, Aura Biosciences ranks #440 out of 1411 companies for Current Ratio. This puts Aura Biosciences in the upper half of its industry. The industry median Current Ratio is 3.91. Aura Biosciences' value of 7.09 is 81.3% above this benchmark. Historically, Aura Biosciences' own Current Ratio has ranged from 5.42 to 27.90 over the past decade. While the company's 10-year median is 14.22 vs. the industry median of 3.91, Aura Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aura Biosciences's current Current Ratio of 7.09 is 81.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aura Biosciences's current Current Ratio is 7.09, which is 50% below median its own 10-year median of 14.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current Current Ratio of 7.09. The current Current Ratio is 7.09, which is 50% below median its 10-year median of 14.22 and 81.3% above the Biotechnology industry median of 3.91. Aura Biosciences' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Aura Biosciences (AURA), the current Current Ratio is 7.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
35GF Score
Get the complete analysis for AURA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURA has been successfully added to your 
